Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
abandoned, Accelerex, acute, Affordable, AHA, alike, allocating, amputation, appointment, ash, asset, attempt, Bandage, bark, botanical, build, capture, care, CE, CEO, chloride, chronic, clinical, close, Closing, closure, code, commercially, consideration, contamination, contingent, contract, counter, Cream, death, Deborah, derived, destruction, device, diabetic, diagnostic, discovered, display, dressing, economy, elevated, environment, extract, fastest, FDA, feature, foot, fourth, fruition, gauze, Getty, government, Gregory, growing, heal, healed, healing, healthcare, high, history, home, hospital, human, immeasurable, immense, impede, impose, impregnated, infection, ingredient, initiative, intellectual, Irene, lack, lead, Library, matrix, member, million, modern, month, ninety, nursing, oak, obesity, obligation, ointment, open, OTC, paid, pain, paramount, Patent, patient, Payee, Payer, pharma, Pilant, population, potassium, precise, pressure, prevalence, property, proportionate, protease, protein, Proteomic, qbx, rate, Red, regenerex, reimbursed, remain, removing, resigned, return, rubidium, scientific, segment, shown, single, sooner, staggering, sterile, successful, suffering, suitable, surgical, Synthetic, technology, thirty, title, Today, transaction, tube, unavailable, USA, variety, wide, work, wound, Woundcare, Xcellderma
Removed:
absorbing, Acid, adjustment, Administration, advance, advantage, advertising, agreed, aimed, algorithmic, Amazon, antioxidant, Apple, approach, Arbutin, assist, August, Azelaic, batch, beautiful, blend, boost, booster, brand, branding, breakdown, Brightening, built, campaign, Canada, catalog, center, chemistry, chronological, Circulation, collection, commenced, communication, concentrated, consistency, content, corporate, Correcting, cosmetic, creating, creative, Creme, crow, custom, cutting, daily, damage, dark, deciding, deeply, delayed, delicate, deliver, delivery, demonstrate, determinable, developed, diminishing, direct, discoloration, disposed, distinct, dramatic, eco, edge, effectively, elasticity, Emblica, encouraging, environmental, Ergothioneine, essential, established, expertise, exposure, eye, fast, fatigue, feet, Ferulic, field, fine, fixed, Food, formation, formulated, formulation, Fragrance, free, funnel, gauge, GMP, Good, guarantee, highest, highly, hydrate, hydrating, hydration, individual, inhibit, innovation, intend, intensive, internally, internet, introduce, inventory, July, leader, leverage, Licorice, lightweight, making, manufactured, manufacturer, master, media, melanin, melasma, Micro, microbiological, modest, moisturizer, molded, nourish, nourishing, offer, order, organically, outsource, packaging, PayPal, percentage, performed, pigment, post, posted, potency, potent, presented, pricing, privately, profound, protection, purity, quickly, radiation, radical, reduction, regulate, regulating, Renewal, repair, researched, resist, resort, restore, reverse, sale, science, select, selecting, September, serum, set, shelf, Shopify, site, slated, software, source, sourcing, spa, space, stability, stable, step, stimulating, store, sun, supplier, supply, support, synergistic, target, targeted, temperature, test, tested, texture, Toiletry, tone, toxicity, ultimate, uneven, Uniquely, unmatched, UV, vetted, visibility, visible, Vitamin, volume, Volumizing, Web, week, Youth
Filing tables
Filing exhibits
RGPX similar filings
Filing view
External links
Exhibit 32.2
CERTIFICATIONS PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
(18 U.S.C. SECTION 1350)
In connection with the Quarterly Report of Regenerex Pharma, Inc. (the ‘Company’) on Form 10-Q for the period ending December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the ‘Report’), I, Irene Getty, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
Registrant | Regenerex Pharma, Inc. | |
Date: February 2, 2022 | By: | /s/ Irene Getty |
Irene Getty | ||
Chief Financial Officer (Principal Financial Officer) |